Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drug Costs Up In Part D With Expanded Use And Price Growth

Executive Summary

Medicare 'Dashboard' spotlights costliest drugs in Part D and Part B programs to help inform public debate around controlling spending increases.

You may also be interested in...



Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

HHS Will Take Anti-Kickback Safe Harbor Proposals For Drug Contracting ‘Seriously,’ US Official Promises

Health and Human Services Department Deputy Secretary Eric Hargan invites biopharma companies to submit proposals on how to modify or create safe harbors that would be suitable for innovative reimbursement contracts involving prescription drugs.

Real World Evidence For Rare Diseases: Payers Cite Lack Of Clarity On Value

Survey of US and European payers suggests manufacturers should 'leverage' key opinion leaders trusted by payers to help drive better understanding and acceptance of real world data.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel